Abstract
Drug interactions involving human immunodeficiency virus protease inhibitors are common due to their inhibition of the cytochrome P450 3A4 isoenzyme. We describe the case of an HIV-infected patient treated with ritonavir-boosted darunavir who developed cushingoid features following an intra-articular injection of triamcinolone acetate. We review the probable mechanism for this interaction and describe similar cases of Cushing syndrome in patients receiving concomitant ritonavir and triamcinolone.
Keywords:
AIDS; Cushing syndrome; HIV; HIV protease inhibitors; antiretrovirals; cobicistat; corticosteroids; drug interactions; ritonavir; toxicity; triamcinolone.
MeSH terms
-
Cushing Syndrome / chemically induced*
-
Cushing Syndrome / diagnosis
-
Cushing Syndrome / drug therapy
-
Darunavir
-
Drug Interactions
-
Female
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / adverse effects*
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / therapeutic use
-
HIV-1
-
Humans
-
Iatrogenic Disease*
-
Injections, Intra-Articular / adverse effects
-
Middle Aged
-
Ritonavir / administration & dosage
-
Ritonavir / therapeutic use*
-
Shoulder Pain / drug therapy*
-
Sulfonamides / administration & dosage
-
Sulfonamides / therapeutic use*
-
Treatment Outcome
-
Triamcinolone / administration & dosage
-
Triamcinolone / adverse effects*
Substances
-
Glucocorticoids
-
HIV Protease Inhibitors
-
Sulfonamides
-
Triamcinolone
-
Ritonavir
-
Darunavir